Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...
Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...
AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...
In studies by Massachusetts General Hospital, the AbbVie-Calico collaborative drug and Denali Therapeutics' own drug failed to meet endpoints for treating amyotrophic lateral sclerosis, more widely ...
Under the terms of the deal, Alchemab and Lilly will work together on up to five new antibodies, according to a Jan. 9 ...
The company said Monday that fosigotifator failed to outperform placebo in slowing the neurodegenerative disease, but is ...
Medpage Today on MSN2d
Herpes and Alzheimer's Tau; Dementia and Autism; Extended Paxlovid for Long COVIDA study of human brain organoids suggested a complex relationship between herpes simplex virus 1 infection and tau, ...
Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...
Most recently, Denali Therapeutics initiated dosing in a global BEACON Phase 2a trial of BIIB122 (DNL151) for LRRK2-associated Parkinson’s disease. Denali’s market cap stands at $2.93 billion ...
Denali Therapeutics Inc. has a 12 month low of $14.56 and a 12 month high of $33.33. Get Denali Therapeutics alerts: Denali Therapeutics (NASDAQ:DNLI – Get Free Report) last released its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback